India's DCGI halves clinical and marketing approval timelines and removes pre‑clinical clearance
Change
India's Drug Controller General of India (DCGI) cut clinical trial approval windows to 120–135 days, capped marketing authorisation decisions at under 150 days, and abolished regulatory clearance for pre‑clinical studies.
Why it matters
Regulatory decisions will be issued in a much shorter, fixed review window, reducing the time available to address deficiencies or submit additional evidence. Allowing pre‑clinical studies to proceed without prior clearance shifts responsibility for study design, data quality and ethical compliance onto sponsors and their trial partners.
Implications
- — Regulatory affairs teams at pharmaceutical and biotechnology companies must finalise and file complete clinical trial and marketing authorisation dossiers immediately — incomplete submissions risk refusal or no opportunity for substantive supplemental filings within the accelerated review windows, causing programme delays.
- — Contract Research Organization (CRO) project managers must verify and deliver fully documented pre‑clinical and clinical study packages before handoff now — missing or weak documentation will materially increase the chance that sponsors' subsequent trial or marketing applications are rejected under the compressed decision timetable.
Unlock the decision layer.
Know what changes, what’s at risk, and what needs action next.
- Implications: What shifts in cost, supply, or compliance.
- Who is affected: Which teams, contracts, or flows are exposed.
- What to watch: Deadlines, triggers, and when action becomes necessary.
- Real-time alerts: Get notified when a change becomes actionable — not noise..
- Ask AI: Go deeper on any change in seconds.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer
Source
Topics